DCDi Chen

Di Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Di Chen has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaowei Li

    Department of Gastroenterology, the Sixth Medical Center of Chinese People’s Liberation Army General Hospital, Beijing, 100080, People’s Republic of China

    2 shared publications
  • Bing Xu

    Department of Gastroenterology Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China

    1 shared publication
  • Bing Xu

    Department of Gastroenterology, Xi’an Jiaotong University Second Affiliated Hospital, Xi’an, China

    1 shared publication
  • Daiming Fan

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China

    1 shared publication
  • Fan Zhou

    Department of Gastroenterology, Nanjing Drum Tower Hospital, Nanjing 210046, China

    1 shared publication
  • Hao Liu

    State Key Laboratory of Cancer Biology & Institute of Digestive Diseases, Xijing Hospital, The Air-Force Military Medical University, Xi'an, Shaanxi, China

    1 shared publication

Latest Publications

  • Open Access

    Pathogenesis of and major animal models used for nonalcoholic fatty liver disease

    by Mingzuo Jiang, Nan Wu, Xi Chen, Weijie Wang, Yi Chu, Hao Liu, Wenjiao Li, Di Chen, Xiaowei Li, Bing Xu

    Nonalcoholic fatty liver disease (NAFLD) and its pathologically more severe form, nonalcoholic steatohepatitis (NASH), have become prevalent worldwide and carry an increased risk of developing hepatocellular carcinoma and other metabolic diseases. Diverse animal models have been proposed to replicate particular characteristics of NAFLD and NASH and have provided significant clues to the critical molecular targets of NASH treatment. In this review, we summarize the histopathology, pathogenesis, and molecular basis of NAFLD progression and discuss the benchmark animal models of NAFLD/NASH.


  • Open Access

    miR-148b-3p inhibits gastric cancer metastasis by inhibiting the Dock6/Rac1/Cdc42 axis

    by Xiaowei Li, Mingzuo Jiang, Di Chen, Bing Xu, Rui Wang, Yi Chu, Weijie Wang, Lin Zhou, Zhijie Lei, Yongzhan Nie, et al.

    Our previous work showed that some Rho GTPases, including Rho, Rac1 and Cdc42, play critical roles in gastric cancer (GC); however, how they are regulated in GC remains largely unknown. In this study, we aimed to investigate the roles and molecular mechanisms of Dock6, an atypical Rho guanine nucleotide exchange factor (GEF), in GC metastasis. The expression levels of Dock6 and miR-148b-3p in GC tissues and paired nontumor tissues were determined by immunohistochemistry (IHC) and in situ hybridization (ISH), respectively. The correlation between Dock6/miR-148b-3p expression and the overall survival of GC patients was calculated by the Kaplan-Meier method and log-rank test. The roles of Dock6 and miR-148b-3p in GC were investigated by in vitro and in vivo functional studies. Rac1 and Cdc42 activation was investigated by GST pull-down assays. The inhibition of Dock6 transcription by miR-148b-3p was determined by luciferase reporter assays. A significant increase in Dock6 expression was found in GC tissues compared with nontumor tissues, and its positive expression was associated with lymph node metastasis and a higher TNM stage. Patients with positive Dock6 expression exhibited shorter overall survival periods than patients with negative Dock6 expression. Dock6 promoted GC migration and invasion by increasing the activation of Rac1 and Cdc42. miR-148b-3p expression was negatively correlated with Dock6 expression in GC, and it decreased the motility of GC cells by inhibiting the Dock6/Rac1/Cdc42 axis. Dock6 was over-expressed in GC tissues, and its positive expression was associated with GC metastasis and indicated poor prognosis of GC patients. Targeting of Dock6 by miR-148b-3p could activate Rac1 and Cdc42, directly affecting the motility of GC cells. Targeting the Dock6-Rac1/Cdc42 axis could serve as a new therapeutic strategy for GC treatment.


  • Open Access

    Down-regulation of LRIG1 by miR-20a modulates gastric cancer multidrug resistance

    by Lin Zhou, Xiaowei Li, Fan Zhou, Zhi’an Jin, Di Chen, Pin Wang, Shu Zhang, Yuzheng Zhuge, Yulong Shang, Xiaoping Zou

    Multidrug resistance (MDR) significantly restricts the clinical efficacy of gastric cancer (GC) chemotherapy, and it is critical to search novel targets to predict and overcome MDR. Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) has been proved to be correlated with drug resistance in several cancers. The present study revealed that LRIG1 was overexpressed in chemo-sensitive GC tissues and decreased expression of LRIG1 predicted poor survival in GC patients. We observed that up-regulation of LRIG1 enhanced chemo-sensitivity in GC cells. Interestingly, miR-20a, which was overexpressed in GC MDR cell lines and tissues, was identified to regulate LRIG1 expression by directly targeting its 3′untranslated region. We also found that inhibition of miR-20a suppressed GC MDR, and up-regulation showed opposite effects. Moreover, we demonstrated that the miR-20a/LRIG1 axis regulated GC cell MDR through EGFR mediated PI3K/AKT and MAPK/ERK signaling pathways. Finally, LRIG1 expression in human GC tissues is inversely correlated with miR-20a and EGFR. Taken together, the newly identified miR-20a/LRIG1/EGFR link provides insight into the MDR process of GC, and targeting this axis represents a novel potential therapeutic strategy to block GC chemo-resistance.